Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must complete TEN-02-301 (PHREEDOM)~Exclusion Criteria:~1. Schedlued for kidney transplant~2. Life expectancy \<12 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenapanor w/Sevelamer (Type: EXPERIMENTAL): Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
- Sevelamer w/Tenapanor (Type: EXPERIMENTAL): Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).